ArticleDermatology and therapy2025

Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study.

Luca Potestio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.